A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study) [EXTENSION OF 700038904].

Trial Profile

A Phase 3 Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Lurasidone in Subjects With Schizophrenia (PEARL 3 Extension Study) [EXTENSION OF 700038904].

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2016

At a glance

  • Drugs Lurasidone (Primary) ; Quetiapine
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEARL-3 extension
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 20 Sep 2016 Results of post hoc analysis from this another phase III study (profile 32428), presented at the 29th Annual Congress of the European College of Neuropsychopharmacology.
    • 31 Mar 2015 Post-hoc analysis of pooled data from this and another phase III trial (CT profile 700023428) presented at the 23rd European Congress of Psychiatry (EPA) 2016, according to a Sunovian Pharmaceuticals media release.
    • 09 Oct 2013 Results presented at the 26th Annual Congress of the European College of Neuropsychopharmacology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top